Metabolic regulation has been proven to play a critical role in T cell antitumor immunity.
However, cholesterol metabolism as a key component of this regulation remains largely …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes degradation of low-density
lipoprotein receptor (LDLR) and plays a central role in regulating plasma levels of LDL …

Elevated LDL-cholesterol (LDLc) levels are a major risk factor for cardiovascular disease
and atherosclerosis. LDLc is cleared from circulation by the LDL receptor (LDLR). Proprotein …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protease that regulates low
density lipoprotein receptor (LDLR) protein levels. The mechanisms of this action, however …

Immunotherapy especially immune checkpoint inhibitors (ICIs) has brought favorable clinical
results for numerous cancer patients. However, the efficacy of ICIs in colorectal cancer …

Background Cancer is emerging as a major problem globally, as it accounts for the second
cause of death despite medical advances. According to epidemiological and basic studies …

In 2003, the sequences of mammalian proprotein convertase subtilisin/kexin type 9 (PCSK9)
were reported. Radiolabeling pulse-chase analyses demonstrated that PCSK9 was …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel
pharmacological target for hypercholesterolemia and associated cardiovascular diseases …

This article reviews the discovery of PCSK9, its structure–function characteristics, and its
presently known and proposed novel biological functions. The major critical function of …

Abstract Purpose of Review Since the discovery of PCSK9 in 2003, this proprotein
convertase was shown to target specific receptors for degradation in endosomes/lysosomes …